<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Tissue plasminogen activator (tPA) is an effective treatment for <z:hpo ids='HP_0001297'>stroke</z:hpo>, but its utility is limited by fear of <z:hpo ids='HP_0001342'>cerebral hemorrhage</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Tenecteplase (TNK), a genetically modified form of <z:mp ids='MP_0002169'>wild-type</z:mp> tPA, exhibits a longer biological half-life and greater fibrin specificity, features that could lead to fewer <z:hpo ids='HP_0001342'>cerebral hemorrhages</z:hpo> than <z:mp ids='MP_0002169'>wild-type</z:mp> tPA in <z:hpo ids='HP_0001297'>stroke</z:hpo> patients </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We injected radiolabeled blood clots into the cerebral circulation of New Zealand White rabbits </plain></SENT>
<SENT sid="3" pm="."><plain>One hour later, we administered tPA (n=57), 0.6 mg/kg TNK (n=43), 1.5 mg/kg TNK (n=27), or vehicle control (n=37) </plain></SENT>
<SENT sid="4" pm="."><plain>A blinded observer examined the brains for macroscopic <z:mp ids='MP_0001914'>hemorrhage</z:mp> using a semiquantitative score </plain></SENT>
<SENT sid="5" pm="."><plain>We estimated thrombolysis by assessing the amount of radiolabel remaining in the cerebral vessels postmortem </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Both <z:mp ids='MP_0002169'>wild-type</z:mp> tPA and TNK caused thrombolysis in most subjects </plain></SENT>
<SENT sid="7" pm="."><plain><z:mp ids='MP_0001914'>Hemorrhage</z:mp> was detected in 26% (6/23) of the control group, 66% (27/41) of the <z:mp ids='MP_0002169'>wild-type</z:mp> tPA group, 55% (16/29) in the 0.6-mg/kg TNK group, and 53% (9/17) in the 1.5-mg/kg TNK group (P:&lt;0.05, chi(2) test) </plain></SENT>
<SENT sid="8" pm="."><plain>The tPA group was statistically significantly different from the control group, but the TNK and tPA groups did not differ from each other </plain></SENT>
<SENT sid="9" pm="."><plain>Neither TNK nor tPA affected the size of the <z:mp ids='MP_0001914'>hemorrhages</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: TNK shows comparable rates of recanalization compared with <z:mp ids='MP_0002169'>wild-type</z:mp> tPA in a model of embolic <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>While tPA increases <z:mp ids='MP_0001914'>hemorrhage</z:mp> rate, the <z:mp ids='MP_0001914'>hemorrhage</z:mp> associated with TNK treatment is not statistically different compared with controls or the tPA group </plain></SENT>
<SENT sid="12" pm="."><plain>These findings suggest that TNK shows promise as an alternative thrombolytic treatment for <z:hpo ids='HP_0001297'>stroke</z:hpo>, but we could not demonstrate improved safety compared with <z:mp ids='MP_0002169'>wild-type</z:mp> tPA </plain></SENT>
</text></document>